| Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling A Janssen, M Hoogendoorn, MH Cnossen, RAA Mathôt, ... CPT: Pharmacometrics & Systems Pharmacology 11 (8), 1100-1110, 2022 | 14 | 2022 |
| Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics ME Cloesmeijer, HLA van den Oever, RAA Mathôt, M Zeeman, ... British journal of clinical pharmacology 86 (8), 1620-1631, 2020 | 13 | 2020 |
| Deep compartment models: a deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling A Janssen, FWG Leebeek, MH Cnossen, RAA Mathôt, ... CPT: Pharmacometrics & Systems Pharmacology 11 (7), 934-945, 2022 | 11 | 2022 |
| Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial I van Moort, T Preijers, LH Bukkems, HCAM Hazendonk, JG van der Bom, ... The Lancet Haematology 8 (7), e492-e502, 2021 | 11 | 2021 |
| SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders MH Cnossen, I van Moort, SH Reitsma, MPM de Maat, REG Schutgens, ... Journal of Thrombosis and Haemostasis 20 (9), 2001-2011, 2022 | 9 | 2022 |
| ChatGPT in pharmacometrics? Potential opportunities and limitations ME Cloesmeijer, A Janssen, SF Koopman, MH Cnossen, RAA Mathôt, ... British journal of clinical pharmacology 90 (1), 360-365, 2024 | 5 | 2024 |
| Impact of enantiomer‐specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis ME Cloesmeijer, MJ van Esdonk, AM Lynn, A Smits, D Tibboel, Y Daali, ... British journal of clinical pharmacology 87 (3), 1443-1454, 2021 | 4 | 2021 |
| Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor … JM Heijdra, W Al Arashi, NCB de Jager, ME Cloesmeijer, LH Bukkems, ... BMJ open 12 (2), e049493, 2022 | 2 | 2022 |
| Quantification of the relationship between desmopressin concentration and Von Willebrand factor in Von Willebrand disease type 1: A pharmacodynamic study JM Heijdra, ME Cloesmeijer, NCB de Jager, FWG Leebeek, MHJA Kruip, ... Haemophilia 28 (5), 814-821, 2022 | 1 | 2022 |
| Desmopressin testing in von Willebrand disease: Lowering the burden JM Heijdra, F Atiq, W Al Arashi, Q Kieboom, E Wuijster, K Meijer, ... Research and practice in thrombosis and haemostasis 6 (6), e12784, 2022 | 1 | 2022 |
| Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of … SNJ Laan, S de Boer, RJ Dirven, I van Moort, TB Kuipers, H Mei, ... Journal of Thrombosis and Haemostasis, 2024 | | 2024 |
| A Generative and Causal Pharmacokinetic Model for Factor VIII in Hemophilia A: A Machine Learning Framework for Continuous Model Refinement A Janssen, L Smalbil, FC Bennis, MH Cnossen, RAA Mathôt, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| Pharmacokinetic–Pharmacodynamic Modelling in Hemophilia A: Relating Thrombin and Plasmin Generation to Factor VIII Activity After Administration of a VWF/FVIII Concentrate LLFG Valke, ME Cloesmeijer, H Mansouritorghabeh, W Barteling, ... European Journal of Drug Metabolism and Pharmacokinetics, 1-15, 2024 | | 2024 |
| Protocol: Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand … JM Heijdra, W Al Arashi, NCB de Jager, ME Cloesmeijer, LH Bukkems, ... BMJ Open 12 (2), 2022 | | 2022 |
| Population Approach Group Europe Population Approach Group Europe M Cloesmeijer | | |
